PreludeDx™ Presents New DCISionRT® Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting ...Middle East

PR Newswire - News
PreludeDx™ Presents New DCISionRT® Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting
DCISionRT with Novel Residual Risk Subtype Identifies Patients Who May Not Benefit from ET after Surgery and Radiation LAGUNA HILLS, Calif., June 7, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast...

Hence then, the article about preludedx presents new dcisionrt data on the effectiveness of endocrine therapy in dcis patients at the asco 2022 annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( PreludeDx™ Presents New DCISionRT® Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting )

Apple Storegoogle play

Last updated :

Also on site :